Clinical Trials on Post - Adolescence Acne in Japan

Total 54 results

GlaxoSmithKline

Completed

Japanese Phase 1 Study of GSK2585823 (JPN P1)

Acne Vulgaris

Japan
GlaxoSmithKline

Completed

A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid After Topical Administration of GSK2585823 in Japanese Subjects With Acne Vulgaris

Acne Vulgaris

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Participants With Acne Vulgaris

Acne Vulgaris

Japan
GlaxoSmithKline

Completed

Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects

Acne Vulgaris

Japan
GlaxoSmithKline

Completed

Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects

Acne Vulgaris

Japan
Galderma R&D

Completed

Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.

Acne Vulgaris

Japan
GlaxoSmithKline

Completed

DUAC® Early Onset Efficacy Study in Japanese Subjects

Acne Vulgaris

Japan
Chiba University

Completed

An Open Study of Tipepidine Hibenzate in Adolescent Patients With Depression

Adolescent | Depression

Japan
GlaxoSmithKline

Terminated

Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)

Stress Disorders, Post-Traumatic | Post-Traumatic Stress Disorder

Japan
Chiba University

Completed

Ifenprodil Tartrate Treatment of Adolescents With Post-traumatic Stress Disorder: a Double-blind, Placebo-controlled Trial

Posttraumatic Stress Disorders

Japan
Galderma R&D

Completed

Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.

Acne Vulgaris

Japan
Galderma R&D

Completed

A Long Term Study of GK530G in Subjects With Acne Vulgaris

Acne Vulgaris

Japan
Daiichi Sankyo Co., Ltd.
Quintiles, Inc.; SRL Medisearch Inc.

Completed

DS-5565 Phase III Study for Post-herpetic Neuralgia

Post-Herpetic Neuralgia

Japan
Toray Industries, Inc

Completed

Efficacy and Safety of TRK-700 in Patient With Post-Herpetic Neuralgia

Post-Herpetic Neuralgia

Japan
Astellas Pharma Inc

Completed

Celecoxib Japan Observational Study for the Patients With Acute Pain

Patients With Traumatic Pain, Post-surgical Pain and Tooth Extract Pain

Japan
Astellas Pharma Inc

Completed

A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients

Bone Marrow Transplantation | Graft Versus Host Disease | Graft-Versus-Host Disease | Graft-Vs-Host Disease

Japan
Astellas Pharma Inc

Completed

A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-

Bone Marrow Transplantation | Graft Versus Host Disease | Graft-Versus-Host Disease | Graft-Vs-Host Disease

Japan
Japan Science and Technology Agency
University of Toyama; Chiba University

Completed

Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-02 Study

Trauma | Posttraumatic Stress Disorder

Japan
Japan Science and Technology Agency
University of Toyama; Chiba University

Completed

Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-01 Study

Trauma | Posttraumatic Stress Disorder

Japan
Daiichi Sankyo Co., Ltd.
CMIC Co, Ltd. Japan

Completed

DS-5565 Phase III Study for Renal Impairment in Japanese Subjects

Diabetic Peripheral Neuropathic Pain | Post-herpetic Neuralgia

Japan
Kibi International University

Unknown

iPad Application-based Intervention for Post-stroke Depression

Post-stroke Depression

Japan
Astellas Pharma Inc

Completed

A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients

Post Operative Pain

Japan
Showa Inan General Hospital

Completed

The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer

Gastric Cancer | Helicobacter Pylori | Eradication | Medical Care Cost

Japan
Eli Lilly and Company

Recruiting

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (CAMPFIRE)

Adolescent | Neoplasms | Child

United States, Spain, United Kingdom, Australia, Italy, Japan, Belgium, France, Germany
Janssen Pharmaceutical K.K.

Completed

A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

Graft vs Host Disease

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder

Autistic Disorder in Children and Adolescents

Japan
Japanese Society for Early Mobilization

Recruiting

The ICU LIBERATION Study (LIBERATION)

Quality of Life | Acute Respiratory Distress Syndrome | Treatment Compliance | Post Intensive Care Syndrome

Japan
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Retrospective And Multicenter Survey To Investigate The Dosage, Efficacy And Safety Of Sertraline In Posttraumatic Stress Disorder Patients

Posttraumatic Stress Disorder

Japan
GlaxoSmithKline

Completed

Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity

Cerebrovascular Accident | Post-Stroke Spasticity

Japan
GlaxoSmithKline

Completed

Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity

Cerebrovascular Accident | Post-Stroke Spasticity

Japan
Novartis Pharmaceuticals

Completed

Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease

Acute Graft Versus Host Disease

Belgium, Japan, Spain, France, Korea, Republic of, Canada, Italy, Denmark
Incyte Corporation

Completed

Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects

Acute Graft-versus-host Disease

Japan
Novartis Pharmaceuticals

Active, not recruiting

Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant

Graft vs Host Disease

Japan, Slovakia, Taiwan, Spain, Korea, Republic of, Thailand, Canada, Russian Federation, Italy, Turkey, India, Czechia, Brazil, Switzerland
Novartis Pharmaceuticals

Terminated

Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN) (EMPHENE)

Post-herpetic Neuralgia

Australia, Taiwan, Germany, France, Portugal, Czechia, United Kingdom, Hungary, Spain, Slovakia, Japan, Canada, Denmark, Norway, Austria, Belgium, Poland, Italy, Korea, Republic of
Pfizer

Terminated

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

United States, Japan
Amgen

Terminated

Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease cGVHD

United States, Japan, France, Belgium
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE)

Primary Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis | Post-Polycythemia Vera-Myelofibrosis

Belgium, Italy, Spain, Bulgaria, Turkey, Greece, Russian Federation, Austria, Canada, Japan, Germany
Zimmer Biomet

Recruiting

Avenir Complete Post-Market Clinical Follow-Up Study

Osteoarthritis, Hip | Avascular Necrosis of Hip | Post-traumatic; Arthrosis | Avascular Necrosis of the Femoral Head

United States, Denmark, Japan, Netherlands, Norway, Sweden
GlaxoSmithKline

Completed

A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity

Spasticity, Post-Stroke

Japan
Novartis Pharmaceuticals

Completed

Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Primary Myelofibrosis (MF) | Post-Polycythemia Vera (PV) MF | Post-Essential Thrombocythemia (ET) MF

Taiwan, Japan, Korea, Republic of, China
Incyte Corporation

Recruiting

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders (LIMBER)

Anemia | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, France, Italy, Japan, United Kingdom, Canada
Alexion Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome

Guillain-Barre Syndrome

Japan
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) (iNTEGRATE)

Chronic Graft Versus Host Disease

United States, Australia, Austria, Canada, China, Croatia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Singapore, Spain, Taiwan
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation (REACH2)

Corticosteroid Refractory Acute Graft vs Host Disease

Germany, Japan, Saudi Arabia, Turkey, United Kingdom, Spain, Canada, Italy, Australia, Austria, France, Korea, Republic of, Hong Kong, Israel, Netherlands, Russian Federation, Denmark, Greece, Taiwan, Norway, Czechia, Bulgaria
CSL Behring

Recruiting

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE)

Acute-graft-versus-host Disease

United States, Korea, Republic of, Spain, Australia, Germany, Italy, Turkey, Japan
Incyte Corporation

Completed

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Graft-versus-host Disease (GVHD)

Belgium, Italy, Spain, Saudi Arabia, Turkey, United Kingdom, Germany, Greece, Canada, Austria, France, Israel, Netherlands, Sweden, Switzerland, Korea, Republic of, Bulgaria, Japan, Norway, Czechia, Russian Federation, Jordan, Hungary, Ind... and more
Millennium Pharmaceuticals, Inc.

Completed

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

Hematopoietic Stem Cells

United States, Spain, Taiwan, Australia, Canada, Singapore, Korea, Republic of, Mexico, Switzerland, Japan, Germany, Norway, Israel, Russian Federation, Hungary, United Kingdom, Italy, Romania, Brazil, France, Austria, Belgium, Port... and more
Incyte Corporation

Active, not recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
Sierra Oncology, Inc.

Completed

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Simplify 1)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Germany, Spain, Israel, Bulgaria, Romania, Japan, Taiwan, Korea, Republic of, Australia, Belgium, Canada, Netherlands, Singapore, Poland, Hungary, Denmark, Sweden, United Kingdom, Czechia, Austria
Incyte Corporation

Active, not recruiting

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, China, Japan, France, Turkey, Germany, Israel, Poland, Belgium, Italy, Austria, Denmark, Finland, Norway

Clinical Trials on Post - Adolescence Acne in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations